Figure 2
![Figure 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1479-5876-11-62/MediaObjects/12967_2012_Article_1442_Fig2_HTML.jpg)
Vaccination schedule with V930 DNA-EP alone (Study 1) and combined V930 DNA-EP→ V932Ad (Study 2). Patients who safely tolerated the highest dose of V930 DNA-EP (2.5 mg/injection) in Study 1 were allowed to enroll directly into Study 2, provided they had completed all 5 V930 vaccinations at least 4 weeks and no more than 24 weeks prior to entry and met all other eligibility criteria.